The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA).
 
Aref Al-Kali
Research Funding - Ambit BioSciences (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Novartis (Inst); Onconova Therapeutics (Inst)
 
Devendra Hiwase
No Relationships to Disclose
 
Maria R. Baer
No Relationships to Disclose
 
Peter Greenberg
Honoraria - H3 Biomedicine
Consulting or Advisory Role - H3 Biomedicine
Research Funding - Celgene (Inst); Genentech (Inst); KaloBios (Inst)
 
Jake Shortt
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Celgene; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Peter MacCallum Cancer Center
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Robert Collins
Employment - University of Texas Southwestern
Honoraria - OptumHealth
Travel, Accommodations, Expenses - OptumHealth; Oregon Health & Science University (OHSU)
 
David P. Steensma
Stock and Other Ownership Interests - ARIAD
Consulting or Advisory Role - Akebia Therapeutics; Amgen; Celgene; H3 Biomedicine; Janssen Oncology; Novartis; Pfizer; Takeda
 
Amit Verma
No Relationships to Disclose
 
Gail J. Roboz
Consulting or Advisory Role - Agios; Amgen; Amphivena; Astex Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Celator; Celgene; Cellectis; CTI; Genoptix; GlaxoSmithKline; Janssen; Juno Therapeutics; MedImmune; MEI Pharma; Novartis; Onconova Therapeutics; Pfizer; Roche; Shire; Sunesis Pharmaceuticals
Research Funding - Abbvie (Inst); Agios (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Cellectis (Inst); CTI (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); MEI Pharma (Inst); Moffitt (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Amphivena; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Celator; Incyte; Janssen; Juno Therapeutics; MEI Pharma; Roche; Shire
 
Jamile M. Shammo
Research Funding - Onconova Therapeutics
 
Oliver G. Ottmann
No Relationships to Disclose
 
John Francis Seymour
No Relationships to Disclose
 
Jeffrey Szer
No Relationships to Disclose
 
Wolfgang Meyer
Employment - Onconova Therapeutics
Stock and Other Ownership Interests - Onconova Therapeutics
 
Patrick Simon Zbyszewski
Employment - Onconova Therapeutics
Stock and Other Ownership Interests - Onconova Therapeutics
 
Michael E. Petrone
Employment - Onconova Therapeutics
Stock and Other Ownership Interests - Onconova Therapeutics
 
Steven M. Fruchtman
Employment - Onconova Therapeutics
Stock and Other Ownership Interests - Onconova Therapeutics
 
Guillermo Garcia-Manero
No Relationships to Disclose
 
Lewis R. Silverman
Consulting or Advisory Role - Onconova Therapeutics
Research Funding - Onconova Therapeutics